help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Srikant, C. B.
Right arrow Articles by Patel, Y. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Srikant, C. B.
Right arrow Articles by Patel, Y. C.

Endocrinology, Vol 110, 2138-2144, Copyright © 1982 by Endocrine Society


ARTICLES

Characterization of pituitary membrane receptors for somatostatin in the rat

CB Srikant and YC Patel

We have demonstrated the presence of specific receptors for somatostatin (SRIF) in normal rat pituitary membranes using ([125I]Tyr11]SRIF) as the radioligand. These receptors bind SRIF with high affinity (Ka approximately 0.47 X 10(10) M-1) and have a maximal binding capacity of 0.095 pmol/mg membrane protein. Two other radioiodinated SRIF analogs which contain N-terminally situated radiolabel, [125I-Tyr1]SRIF and [125I-N-Tyr] SRIF, were found unsuitable for receptor binding studies due to loss of the radiolabel from the ligand molecule under the experimental conditions employed. Binding of [125I]Tyr11]SRIF to these receptors was specific and was not influenced by a variety of other neuropeptides. The specificity of SRIF receptors was also examined using 10 synthetic SRIF analogs as well as catfish somatostatin I. Catfish somatostatin I was 8.3 times less potent than SRIF in binding to SRIF receptors, although it has been reported to be equipotent in terms of in vitro GH inhibition. Analogs which exhibit greater potency for GH inhibition in vitro bound to these receptors with greater affinities than SRIF, whereas biologically inactive analogs showed markedly reduced binding, suggesting that the in vitro GH inhibitory actions of SRIF analogs are related to their ability to interact with SRIF receptors.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society